Oxymatrine-mediated prevention of amyloid β-peptide-induced apoptosis on Alzheimer’s model PC12 cells: in vitro cell culture studies and in vivo cognitive assessment in rats

Yue Zhu,Zhuo Wang,Chao Gao,Lei Zhang,Rubo Sui
DOI: https://doi.org/10.1007/s10787-023-01291-0
2023-07-29
Inflammopharmacology
Abstract:Alzheimer’s disease (AD) is a major neurological disease affecting elderly individuals worldwide. Existing drugs only reduce the symptoms of the disease without addressing the underlying causes. Commonly, Aβ25–35 peptide aggregation is the main reason for AD development. Recently, the discovery of multiple protein-targeting molecules has provided a new strategy for treating AD. This study demonstrates the neuroprotective potential of oxymatrine against multiple mechanisms, such as acetylcholinesterase, mitochondrial damage, and β-amyloid-induced cell toxicity. The in vitro cell culture studies showed that oxymatrine possesses significant potential to inhibit acetylcholine esterase and promotes antioxidant, antiapoptotic effects while preventing Aβ25–35 peptide aggregation in PC12 cells. Furthermore, oxymatrine protects PC12 cells against Aβ25–35-induced cytotoxicity and down-regulates the reactive oxygen species generation. The in vivo acute toxicological studies confirm the safety of oxymatrine without causing organ damage or death in animals. Overall, this study provided evidence that oxymatrine is an efficient neuroprotective agent, with a potential to be a multifunctional drug for Alzheimer’s disease treatment. These findings present a reliable and synergistic approach for treating AD.
immunology,toxicology
What problem does this paper attempt to address?